Literature DB >> 3806426

Schedule for Affective Disorders and Schizophrenia--Lifetime Version modified for the study of anxiety disorders (SADS-LA): rationale and conceptual development.

S Mannuzza, A J Fyer, D F Klein, J Endicott.   

Abstract

The SADS-LA, a modification of the Lifetime Version of the Schedule for Affective Disorders and Schizophrenia, was designed specifically for studies requiring detailed lifetime information on anxiety disorders, symptoms and traits. This article focuses on current difficulties in assessing and conceptualizing anxiety disorders, as addressed in the SADS-LA. The following topics are discussed: conceptual differentiation of certain anxiety disorders; sub-threshold symptoms and syndromes; the relationship between affective and anxiety syndromes; the residual category, Generalized Anxiety Disorder. We emphasize a lifetime sequential approach to diagnostic assessment for a comprehensive understanding of the interrelationships between mental disorders.

Entities:  

Mesh:

Year:  1986        PMID: 3806426     DOI: 10.1016/0022-3956(86)90034-8

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  94 in total

1.  No evidence for DUP25 in patients with panic disorder using a quantitative real-time PCR approach.

Authors:  Johannes Schumacher; Andreas C J Otte; Tim Becker; Yuli Sun; Thomas F Wienker; Brunhilde Wirth; Petra Franke; Rami Abou Jamra; Peter Propping; Jürgen Deckert; Markus M Nöthen; Sven Cichon
Journal:  Hum Genet       Date:  2003-09-25       Impact factor: 4.132

2.  Linkage analysis of alternative anxiety phenotypes in multiply affected panic disorder families.

Authors:  Abby J Fyer; Ramiro Costa; Fatemeh Haghighi; Mark W Logue; James A Knowles; Myrna M Weissman; Susan E Hodge; Steven P Hamilton
Journal:  Psychiatr Genet       Date:  2012-06       Impact factor: 2.458

3.  The Influence of Paternal and Maternal Major Depressive Disorder on Offspring Psychiatric Disorders.

Authors:  Rachel H Jacobs; Ardesheer Talati; Priya Wickramaratne; Virginia Warner
Journal:  J Child Fam Stud       Date:  2014-09-02

4.  A comparison between screened NIMH and clinically interviewed control samples on neuroticism and extraversion.

Authors:  A Talati; A J Fyer; M M Weissman
Journal:  Mol Psychiatry       Date:  2007-10-16       Impact factor: 15.992

5.  ADHD familial loading and abnormal EEG alpha asymmetry in children with ADHD.

Authors:  T Sigi Hale; Susan L Smalley; Jeff Dang; Grant Hanada; James Macion; James T McCracken; James J McGough; Sandra K Loo
Journal:  J Psychiatr Res       Date:  2009-12-16       Impact factor: 4.791

6.  The impact of gender and age at onset on the familial aggregation of schizophrenia.

Authors:  W Maier; D Lichtermann; J Minges; R Heun; J Hallmayer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

7.  Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR).

Authors:  L J Strug; R Suresh; A J Fyer; A Talati; P B Adams; W Li; S E Hodge; T C Gilliam; M M Weissman
Journal:  Mol Psychiatry       Date:  2008-07-29       Impact factor: 15.992

8.  Depression in the community: a comparison of treated and non-treated cases in two non-referred samples.

Authors:  W Maier; D Lichtermann; A Oehrlein; M Fickinger
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder.

Authors:  Sandeep Gyawali; Ryan Subaran; Myrna M Weissman; Dylan Hershkowitz; Morgan C McKenna; Ardesheer Talati; Abby J Fyer; Priya Wickramaratne; Phillip B Adams; Susan E Hodge; Carl J Schmidt; Michael J Bannon; Charles E Glatt
Journal:  Biol Psychiatry       Date:  2009-12-06       Impact factor: 13.382

10.  Social functioning difficulties in ADHD: association with PDD risk.

Authors:  Erika Carpenter Rich; Sandra K Loo; May Yang; Jeff Dang; Susan L Smalley
Journal:  Clin Child Psychol Psychiatry       Date:  2009-07       Impact factor: 2.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.